JP2022513626A - Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド - Google Patents

Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド Download PDF

Info

Publication number
JP2022513626A
JP2022513626A JP2021529265A JP2021529265A JP2022513626A JP 2022513626 A JP2022513626 A JP 2022513626A JP 2021529265 A JP2021529265 A JP 2021529265A JP 2021529265 A JP2021529265 A JP 2021529265A JP 2022513626 A JP2022513626 A JP 2022513626A
Authority
JP
Japan
Prior art keywords
seq
lpl
polypeptide
fusion polypeptide
gpihbp1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021529265A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020109978A5 (https=
JP2022513626A5 (https=
Inventor
ガオ，ジアピン
ニモンカー，アミタブー
トラウガー，ジョン
イゴレビッチ ボズネセンスキ，アンドレイ
クレイグ ウェルドン，スティーブン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2022513626A publication Critical patent/JP2022513626A/ja
Publication of JPWO2020109978A5 publication Critical patent/JPWO2020109978A5/ja
Publication of JP2022513626A5 publication Critical patent/JP2022513626A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01034—Lipoprotein lipase (3.1.1.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2021529265A 2018-11-26 2019-11-25 Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド Pending JP2022513626A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862771359P 2018-11-26 2018-11-26
US62/771,359 2018-11-26
PCT/IB2019/060140 WO2020109978A1 (en) 2018-11-26 2019-11-25 Lpl-gpihbp1 fusion polypeptides

Publications (3)

Publication Number Publication Date
JP2022513626A true JP2022513626A (ja) 2022-02-09
JPWO2020109978A5 JPWO2020109978A5 (https=) 2022-12-05
JP2022513626A5 JP2022513626A5 (https=) 2022-12-05

Family

ID=68807212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021529265A Pending JP2022513626A (ja) 2018-11-26 2019-11-25 Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド

Country Status (5)

Country Link
US (1) US20220025344A1 (https=)
EP (1) EP3887393A1 (https=)
JP (1) JP2022513626A (https=)
CN (1) CN113396158A (https=)
WO (1) WO2020109978A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117384912A (zh) * 2023-12-13 2024-01-12 中国人民解放军东部战区总医院 Gpihbp1突变型基因及其应用
WO2025124559A1 (zh) * 2023-12-13 2025-06-19 维亚臻生物技术（苏州）有限公司 捕获探针、含有其的家族性乳糜微粒血症综合征检测试剂盒及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018020477A1 (en) * 2016-07-28 2018-02-01 The Regents Of The University Of California Methods and compositions for treating hypertriglyceridemia

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
ITMI20011483A1 (it) 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
JP5290489B2 (ja) 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
CN101584858A (zh) 2005-12-20 2009-11-25 布里斯托尔-迈尔斯斯奎布公司 稳定蛋白质制剂
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2011144756A1 (en) 2010-05-21 2011-11-24 Xl-Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
AR087329A1 (es) * 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
JP6803236B2 (ja) 2014-06-10 2020-12-23 アムジェン インコーポレイテッド アペリンポリペプチド
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018020477A1 (en) * 2016-07-28 2018-02-01 The Regents Of The University Of California Methods and compositions for treating hypertriglyceridemia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELIFE, vol. 5:e12095, JPN6023042213, 2016, ISSN: 0005175101 *
JOURNAL OF LIPID RESEARCH, vol. 58, no. 9, JPN6023042212, 2017, pages 1893 - 1902, ISSN: 0005175102 *

Also Published As

Publication number Publication date
US20220025344A1 (en) 2022-01-27
WO2020109978A1 (en) 2020-06-04
EP3887393A1 (en) 2021-10-06
CN113396158A (zh) 2021-09-14

Similar Documents

Publication Publication Date Title
US11840558B2 (en) Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
JP6930756B6 (ja) Ｐ９７−ｉｄｓ融合タンパク質
US20240279296A1 (en) Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same
CA3003115C (en) DUAL-FUNCTION PROTEINS AND PHARMACEUTICAL COMPOSITION INCLUDING
KR101993714B1 (ko) 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
JP4344136B2 (ja) アポリポタンパク質類似体
US20200224184A1 (en) Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
KR20190104958A (ko) 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체
WO2018003983A1 (ja) ｈＡＮＰ－Ｆｃ含有分子コンジュゲート
EP3678687B1 (en) Mutant fgf-21 peptide conjugates and uses thereof
KR20170065026A (ko) 대사 장애 치료용으로 이용되는 조성물 및 방법
EP3642338B1 (en) Fusion protein with half-life extending polypeptide
CN102272163A (zh) 瘦素和瘦素类似物结合物及其用途
US20180280474A1 (en) Treatment of bile acid disorders
JP2019535267A (ja) Ｇｄｎｆ融合ポリペプチド及びその使用方法
KR20230059777A (ko) 요산산화효소-알부민 접합체, 그 제조방법 및 용도
Meng et al. Clinical application of polysialylated deoxyribonuclease and erythropoietin
JP2022513626A (ja) Ｌｐｌ－ｇｐｉｈｂｐ１融合ポリペプチド
KR20190003546A (ko) 컨쥬게이트 c1 에스테라제 억제제 및 그의 용도
HK40015865A (en) Gdnf fusion polypeptides and methods of use thereof
BR112016018721B1 (pt) Proteína de fusão p97 (melanotransferrina), composição farmacêutica que compreende a dita proteína de fusão e uso da proteína de fusão para tratar uma doença de depósito lisossômico

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231017

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240514